About US
Contact us
-
NICE asks for more info on first-line Tarceva useThe U.K.'s cost-effectiveness watchdog has asked Roche ($RHHBY) for more information on Tarceva as a first-line treatment for non-small cell lung cancer. The National Institute for Health and Clini2012/2/20
-
Novartis to revamp Rasilez label with safety risksThe data on Rasilez's safety risks is coming home to roost. The Novartis ($NVS) blood-pressure drug will get a new warning in Europe at regulators' request, after a recent trial flagged links to strok2012/2/20
-
Wyeth puts $960M squeeze on Sun for Protonix launchSun Pharmaceuticals' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ($PFE) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's v2012/2/17
-
Leukemia drug shortage averted for now, FDA saysDisaster averted, say federal health officials. HHS Secretary Kathleen Sebelius told Congress yesterday that new supplies of the critically scarce drug methotrexate would be released in the coming day2012/2/17
-
Teva scrambling toward post-Copaxone futureTeva Pharmaceutical Industries ($TEVA)has been the world's biggest generics player for years. Problem is, it's trying to be more than that. And makeovers take time. Midway throughlast year, analysts w2012/2/16
-
A bright side to Europe's woes: U.S., Japan look betterEurope is making the U.S. and Asia look much sweeter to drugmakers. Price cuts, slow adoption of new medicines, and, of course, unpaid bills, have disillusioned pharma companies accustomed to counting2012/2/16
-
Old drug + potential new use = headache for pharmaPotential new uses for approved drugs crop up regularly. Most drug companies build their business plans around adding indications to new products; after all, the more patients who are eligible to us2012/2/15
-
GSK's office-space overhaul part of bigger changesGlaxoSmithKline ($GSK) employees in the Philadelphia area face big changes in the way they work as the company prepares to relocate to a new building in the Navy Yard. But those changes are only part2012/2/15
-
Lonza teams with S. Africa on antiretroviral API plantSwiss drug manufacturer Lonza has allied with the South African government on a new, $210 million plant to produce antiretroviral APIs. The venture, dubbed Ketlaphela, is aimed at reducing drugmaker2012/2/14
-
Gene study finds tumor-cell flaw possibly vulnerable to Pfizer, AZ cancer medsMore evidence that drugs and diagnostics will be playing together often: Researchers sequencing genes in colon and lung tumors found mutations that could be targeted with existing drugs. The study e2012/2/14